Late-breaking poster presentations (as of 9/20/23)

Poster Session A
Thursday, October 12 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivo. Ulrike Rauh, Trueline Therapeutics Inc., Berlin, Germany.

LB_A02: Predicting breast cancer patients’ response to neoadjuvant chemotherapy from the deconvolved transcriptome of different cell types in the tumor microenvironment. Saugato Rahman Dhruba, National Cancer Institute, National Institutes of Health, Bethesda, MD United States.

LB_A03: Proximity ligation sequencing reveals novel and recurrent structural genomic variants in FFPE pancreatic ductal adenocarcinoma samples. Abhishek Pandey, University of Colorado Comprehensive Cancer Center, Aurora, CO United States.


LB_A05: Coadministration of AZD 4573 and gilteritinib exhibits a potent activity in FLT3 inhibitor-sensitive and -resistant AML cells. Mohamed Rahami, College of Medicine, Sharjah Institute for Medical Research, University of Sharjah; College of Medicine & Health Sciences, Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates.

LB_A07: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial. Jessica J Lin, Massachusetts General Hospital, Harvard Medical School, Boston, MA United States.


LB_A12: Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor. Lisa Mahnke, Nerviano Medical Sciences Inc., Boston, MA United States.

LB_A13: Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer. Gerald Steven Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO United States.

LB_A14: Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trials. Deborah B. Doroshow, Icahn School of Medicine at Mount Sinai, New York, NY United States.

LB_A16: Dareon™-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas. Valentina Gambardella, Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, Valencia, Spain.

LB_A19: Genome-wide CRISPR/Cas9 screens for the identification of targeted vulnerabilities in PARP inhibitor-resistant PARG;BRCA2-deficient tumor cells: A focus on EXO1/FEN1-mediated DNA repair. Christina Andronikou, Netherlands Cancer Institute, Amsterdam, Netherlands.


LB_A21: NCI60 HTS384: The next phase of the NCI60 screen. Beverly A. Teicher, NCI, Rockville, MD United States.

LB_A22: Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights. Ali H. Ibrahim, MD Anderson Cancer Center, Houston, TX United States.

LB_A23: The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle Differentiation. Ashwaq K. Aljabri, NIH, Frederick, MD United States.

LB_A24: Baicalein suppresses tumorigenesis of the ER positive of breast cancer cells by targeting multiple signaling pathways. Besa Xhabija, University of Michigan- Dearborn, Dearborn, MI United States.

LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation. Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY United States.